The Journal of

PHARMACOLOGY
And Experimental Therapeutics

A Publication of the American Society for Pharmacology and Experimental Therapeutics

February 2022
Vol. 380, No. 2

Contents

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Evidence for Alpha7 Nicotinic Receptor Activation During the Cough Suppressing Effects Induced by Nicotine and Identification of ATA-101 as a Potential Novel Therapy for the Treatment of Chronic Cough
Brendan J. Canning, Qi Liu, Mayuko Tao, Robert DeVita, Michael Perelman, Douglas W. Hay, Peter V. Dicpinigatis, and Jing Liang

METABOLISM, TRANSPORT, AND PHARMACOGENETICS

Novel Bile Acid-Dependent Mechanisms of Hepatotoxicity Associated with Tyrosine Kinase Inhibitors
Chitra Saran, Louise Sundqvist, Henry Ho, Jonna Niskanen, Paavo Honkakoski, and Kim L. R. Brouwer

NEUROPHARMACOLOGY

Intravenous and Intramuscular Allopregnanolone for Early Treatment of Status Epilepticus: Pharmacokinetics, Pharmacodynamics, and Safety in Dogs

Post-Stroke Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Attenuates Chronic Changes in Brain Metabolism, Increases Neurotransmitter Levels, and Improves Recovery

ERRATUM

Correction to “Antinociceptive and Discriminative Stimulus Effects of Six Novel Psychoactive Opioid Substances in Male Rats”

Supplemental material is available at jpet.aspetjournals.org.

About the cover: Novel mechanisms of tyrosine kinase inhibitor (TKI)-induced hepatic injury. See the article by Saran et al. (dx.doi.org/10.1124/jpet.121.000828).